Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration

Age-related macular degeneration (AMD) is a global health concern and the leading cause of vision loss in the developed world. Intravitreal anti-vascular endothelial growth factor (VEGF) therapy has revolutionized the treatment of neovascular AMD, but there are still challenges with delivery of care...

Descripción completa

Detalles Bibliográficos
Autores principales: Yannuzzi, Nicolas A, Freund, K Bailey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661993/
https://www.ncbi.nlm.nih.gov/pubmed/31413539
http://dx.doi.org/10.2147/OPTH.S184706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661993/
https://www.ncbi.nlm.nih.gov/pubmed/31413539
http://dx.doi.org/10.2147/OPTH.S184706

Ejemplares similares